JAGX
NASDAQ · Pharmaceuticals
Jaguar Health Inc
$0.97
+0.03 (+3.11%)
Financial Highlights (FY 2026)
Revenue
847.32M
Net Income
-3,933,246,142
Gross Margin
67.2%
Profit Margin
-464.2%
Rev Growth
-1.3%
D/E Ratio
3.64
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 67.2% | 67.2% | 61.3% | 61.3% |
| Operating Margin | -414.4% | -373.0% | 27.6% | 29.3% |
| Profit Margin | -464.2% | -441.0% | 23.6% | 22.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 847.32M | 858.13M | 728.2K | 878.3K |
| Gross Profit | 569.48M | 576.75M | 446.4K | 538.4K |
| Operating Income | -3,511,710,209 | -3,200,870,152 | 200.8K | 257.3K |
| Net Income | -3,933,246,142 | -3,585,093,708 | 171.9K | 200.8K |
| Gross Margin | 67.2% | 67.2% | 61.3% | 61.3% |
| Operating Margin | -414.4% | -373.0% | 27.6% | 29.3% |
| Profit Margin | -464.2% | -441.0% | 23.6% | 22.9% |
| Rev Growth | -1.3% | -1.3% | -5.9% | +16.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.86M | 1.86M | 719.4K | 546.9K |
| Total Equity | 512.2K | 512.2K | 1.37M | 1.50M |
| D/E Ratio | 3.64 | 3.64 | 0.52 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -3,370,870,381 | -3,243,191,069 | 249.9K | 289.1K |
| Free Cash Flow | — | — | 132.1K | 184.4K |